
Sign up to save your podcasts
Or


While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
By ReachMD4
11 ratings
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.

3 Listeners

3 Listeners

0 Listeners

6 Listeners

15 Listeners

18 Listeners

0 Listeners